Sonoma Biotherapeutics Raises $265 Million In An Oversubscribed Series B Financing To Translate The Promise Of Cell Therapy Into Curative Medicines For Autoimmune And Other Inflammatory Diseases
Amount Raised
$265 Million
Round Type
Series B
San FranciscoBiotechnologyDescription
Sonoma Biotherapeutics, an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, has announced an oversubscribed $265 million Series B financing. Proceeds from the financing will be used to advance Sonoma Bio’s Treg cell therapy platform and a novel Teff conditioning biologic into the clinic to treat multiple, severe autoimmune and inflammatory diseases and to further invest in and scale up manufacturing operations in order to support supply for initial clinical studies.
Quick answer
Sonoma Biotherapeutics raised $265 Million in a Series B round, dated August 4, 2021. Sonoma Biotherapeutics is based in San Francisco, California, United States.
- How much did Sonoma Biotherapeutics raise?
- Sonoma Biotherapeutics raised $265 Million in a Series B round on August 4, 2021.
- What does Sonoma Biotherapeutics do?
- Sonoma Biotherapeutics is a South San Francisco and Seattle-based clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by..
- Where is Sonoma Biotherapeutics based and how big is it?
- Sonoma Biotherapeutics is based in San Francisco, California, United States. Fundz records about 113 employees.
- Who are the decision-makers at Sonoma Biotherapeutics?
- Fundz holds 1 contact at Sonoma Biotherapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Sonoma Biotherapeutics that raised within 45 days of this round, from Fundz verified event records.
- Triana Biomedicines raised $10M on September 17, 2021.
- Enkefalos Biosciences, Inc. raised $1.5M (Seed) on September 17, 2021.
- Membrion raised $3M (Seed) on September 17, 2021.
- NEXGEL raised $1.6M (Seed) on September 17, 2021.
- Biolinq raised $62M on September 17, 2021.
- Iaso Bio raised $108M (Series C) on September 16, 2021.
Who to call at Sonoma Biotherapeutics, and when
A new round usually means Sonoma Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Sonoma Biotherapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sonoma Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sonoma Biotherapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sonoma Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSonoma Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.